Beijing University of Chinese Medicine, Beijing, China.
Keio University, Tokyo, Japan.
Integr Cancer Ther. 2020 Jan-Dec;19:1534735420928466. doi: 10.1177/1534735420928466.
LC09 is composed with 5 kinds of traditional Chinese herbal medicines (, flowers carthami, lithospermum, geranium wilfordii, and radix angelicae) which are used in China and developed over several thousand years. To assess the effectiveness and safety of herbal compound LC09 on patients with capecitabine-associated hand-foot syndrome (HFS). In this randomized, double-blind, and parallel-controlled study, 156 patients that diagnosed with HFS were randomly assigned to a treatment group (n = 78) or control group (n = 78). Patients were evaluated every week by the National Cancer Institute (NCI) grade and Numerical Rating Scale (NRS) pain scores. The Dermatology Life Quality Index (DLQI) scale and Instrumental Activity of Daily Living (IADL) scale were used to assess the quality of life before the treatment, and at 1 week and after the treatment of 2 cycles. At the baseline, no significant differences were observed between the 2 groups. After treatment, significant differences in NCI grade and NRS pain scores were observed between the 2 groups ( < .01). In addition, HFS effectiveness rate and pain alleviation rate were significantly higher in the treatment group compared with the control group ( < .01). Furthermore, the chemotherapy completion rate between 2 groups was significantly different ( = .002). In addition, no adverse reactions were observed in either LC09 or control group. LC09 can decrease NCI grade and significantly alleviate pain in HFS patients. Besides, it can also increase chemotherapy completion rate.
LC09 由 5 种中草药(红花、紫草、地榆、千里光和当归)组成,这些草药在中国被使用了数千年。 本研究旨在评估 LC09 对卡培他滨相关性手足综合征(HFS)患者的有效性和安全性。 这是一项随机、双盲、平行对照研究,共纳入 156 例 HFS 患者,随机分为治疗组(n = 78)和对照组(n = 78)。每周采用 NCI 分级和 NRS 疼痛评分对患者进行评估。在治疗前、治疗 2 个周期后 1 周,采用皮肤病生活质量指数(DLQI)和日常生活活动量表(IADL)评估患者的生活质量。 治疗前,两组间无显著差异。治疗后,两组间 NCI 分级和 NRS 疼痛评分均有显著差异( <.01)。此外,治疗组 HFS 有效率和疼痛缓解率明显高于对照组( <.01)。此外,两组间化疗完成率差异有统计学意义( =.002)。此外,LC09 组和对照组均未观察到不良反应。 LC09 可降低 HFS 患者的 NCI 分级并显著缓解疼痛,还可提高化疗完成率。